deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT03454893

Open Label, Study Of Efficacy and Safety Of AVR-RD-01 for Treatment-Naive Subjects With Classic Fabry Disease

An Open-Label, Multinational Study Of The Efficacy And Safety of Ex Vivo, Lentiviral Vector-Mediated Gene Therapy AVR-RD-01 For Treatment-Naive Subjects With Classic Fabry Disease

Sponsor: AVROBIO

Conditions Fabry Disease
Interventions AVR-RD-01
Updated 14 times since 2018 Last updated: Jan 3, 2024 Started: Feb 21, 2018 Primary completion: Mar 14, 2022 Completion: Mar 14, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

AVROBIO has deprioritized its Fabry disease program

Other terminated trials from AVROBIO

More terminations from AVROBIO

Other Fabry Disease trials with similar outcome

Browse all Fabry Disease trials

This PHASE1/PHASE2 trial investigates Fabry Disease and is currently terminated or withdrawn. AVROBIO leads this study, which shows 14 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Mar 2018 – ~Apr 2018 · 31 days · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Aug 2019 · 14 months · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Mar 2020 · 6 months · monthly snapshot~Mar 2020 – ~Dec 2020 · 9 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Mar 2022 · 14 months · monthly snapshot~Mar 2022 – ~May 2022 · 2 months · monthly snapshot~May 2022 – ~Dec 2022 · 7 months · monthly snapshot~Dec 2022 – ~Feb 2024 · 14 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Feb 2024 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

  4. Dec 2022 — Feb 2024 [monthly]

    Terminated PHASE1_PHASE2

  5. May 2022 — Dec 2022 [monthly]

    Terminated PHASE1_PHASE2

    Status: Recruiting → Terminated

▶ Show 9 earlier versions

  1. Mar 2022 — May 2022 [monthly]

    Recruiting PHASE1_PHASE2

  2. Jan 2021 — Mar 2022 [monthly]

    Recruiting PHASE1_PHASE2

  3. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  4. Mar 2020 — Dec 2020 [monthly]

    Recruiting PHASE1_PHASE2

  5. Sep 2019 — Mar 2020 [monthly]

    Recruiting PHASE1_PHASE2

  6. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE1_PHASE2

  7. Jun 2018 — Aug 2019 [monthly]

    Recruiting PHASE1_PHASE2

  8. Apr 2018 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  9. Mar 2018 — Apr 2018 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Feb 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AVROBIO
Data source: AVROBIO

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations